You must know that no one can accurately answer your question. "The Market" has a set of assumptions built-in, related to future sales, future profit, future dividends, future of the development portfolio, etc. The stock will move (up or down) as indicators or facts are shared that make "The Market" either change its assumptions or its confidence in the assumptions.
I am a long-time long and HOPE the stock returns to yearly gains, based on developing its portfolio successfully. I don't think any one piece of information will cause a turnaround. What we really need is a string of positive data (eg - new approvals, new progressions of drugs through the pipeline, new management?, new deals, etc)
I speculated last month that the company's early November statement implied early December, rather than "late December". I still think that the company believed, at that time, that the results would be available before the last week of December. The only valid reason to change my view is based on facts or statements from the company. The only relevant fact is the results are not yet available. I have not seen any statement from the company that suggests a delay into next year. My conclusion is that, based on all available information, the results will be made public by Dec 31. Anything else is speculation, unless/until the company updates the date.
so, you're saying that "bad data" are material, but "good data" are not? There is no plausible defense of your comments.
Volume is heavy (for this stock), but I'm not sure what to make of the fact that only about 2.5 million dollars has changed hands on a stock with a market cap of 200 million. Good news (I think), but not sure what's behind it.
I believe AstraZeneca finalized the development and has commercialized Cubicin. i wonder why they did not offer (maybe they did?) to buy the follow-up compound, or the whole company.
As for our buyout, just be patient. When the time, and return are right, it will happen.
what was it about "the way that it traded" that suggests news is coming on Monday? It doesn't look to me any different that it did yesterday.
Wait, it WAS just Tuesday. Ouch! BOHICA
BWLD has a P/E ratio of 33; CBRL is currently at 22.
If you believe that these 2 companies should be valued in a comparable way, it leaves plenty of upside for CBRL (or, downside for BWLD!). I haven't checked, but do you know what the estimates are for expansion for each of these 2 companies?
I don't know specifically about the ACHN options, but all option schemes I have seen from other companies have the options 100% vest immediately upon a change of control.
YES INDEED!!! Continued price increase on low volume. Just between you and me, here's what we know.....the POC results will be out later this month, and we longs are becoming increasingly resistant to selling any shares, until those results are out.
The following is directly from their earnings release on November 12. I would expect the results to be made public no later than the first 2 weeks of January.....public results before the end of the year are possible, but not promised.
The company announced today that enrollment in the Phase 2b ACLF trial has been concluded and dosing has been completed. Aggregate top-line PK/PD data from the ACLF trial, with 21 subjects, the renal impairment trial, with 16 subjects, and the hepatic impairment trial, with 36 subjects, are expected to be available to the company by year-end 2014 and to be reported publicly shortly thereafter. Aggregate final data from these three trials, encompassing a total of 73 subjects across five distinct organ impairment patient populations, are expected to be sufficient to determine the optimal dosing of emricasan. These data will also help determine the future direction for the clinical development of emricasan in potential future studies over a broad range of patient populations, including critically ill patients with varying degrees of liver and kidney function.
All I can say is, "Don't blame ACHN!" On Nov 4, they said that the POC results would be available "later this quarter". From the posts below, it appears (I am not listening in) they said today that the results will be available by the end of the year. I would guess their PR people would prefer to stick with the same wording - ie - later this quarter, but there is no difference in the bottom line from Nov 4 until today.
There is plenty of speculation (based on what, I don't know?), but ACHN has not changed their position (at least not since Nov 4).